321547-49-3

Upstream product

• 252364-42-4 (+/-)-α-[2-methoxy-3-[(1,1-dimethylethyldiphenylsilyl)oxy]phenyl]-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanone 
• 332-42-3 (2-bromoethyl)-4-fluorobenzene 
• 311348-75-1 (+/-)-α-[2-methoxy-3-[(1,1-dimethylethyl)diphenylsilyl]oxyphenyl]-4-piperidinemethanol 

Downstream Products

• 321547-50-6 sulfuric acid mono-(+/-)-[3-({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxymethyl)-2-methoxy-phenyl]ester 
• 1402843-07-5 (2-methoxy-3-(tosyloxyethyloxy)phenyl)-(1-(2-p-fluorophenylethyl)-piperidine-4-yl)-methyl acetate 
• 1018473-94-3 [3-(2-[18F]fluoroethoxy)-2-methoxyphenyl]-1-[2-(4-fluorophenyl)ethyl-4-piperidinyl]methanol 
• 1402843-08-6 C₂₅H₃₁F⁽¹⁸⁾FNO₄ 

Relevant academic research and scientific papers

Direct radiofluorination of [18F]MH.MZ for 5-HT2A receptor molecular imaging with PET

Imaging the serotonin 2A neuroreceptor with positron emission tomography has been carried out with [11C]MDL 100907 and [18F] altanserin for years. Recently, the MDL 100907 analogue [18F]MH.MZ was developed by combining the

Sulfuric acid mono-[3({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester

The present invention is directed to sulfuric acid mono-[3-({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester a metabolite of the 5HT2Aantagonist (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-pipe